Abstract
Agonists of the peroxisome proliferator activated receptor gamma (PPARγ) have been shown to reduce inflammatory responses in several animal models of neurological diseases and conditions and to reduce amyloid burden in transgenic mice expressing mutant forms of human amyloid precursor protein. However, the effects of activating the related receptor PPARdelta (PPARδ), which is expressed at higher levels in the brain than PPARγ, on inflammation and amyloid burden have not been explored. In this study we tested the effects of the selective PPARδ agonist GW742 in 5xFAD mice which harbor 3 mutations in amyloid precursor protein and 2 mutations in presenilin 1, develop plaques by 5-6 weeks of age, and show robust inflammation and neuronal damage. Oral delivery of GW742 significantly reduced amyloid plaque burden in the subiculum region of 3-month old male and female 5xFAD mice. GW742 also significantly reduced astrocyte activation, suggesting anti-inflammatory effects on glia cells. The changes in plaque burden were accompanied by increased expression of the amyloid degrading enzymes neprilysin and insulin degrading enzyme, while in transfected HEK293 cells, GW742 activated a neprilysin promoter driving luciferase expression. These results suggest that, as found for some PPARγ agonists, PPARδ agonists can also reduce amyloid burden likely to be mediated by effects on amyloid clearance.
Keywords: Amyloid, neprilysin, astrocyte, promoter, inflammation, NEP, IDE
Current Alzheimer Research
Title: A PPARdelta Agonist Reduces Amyloid Burden and Brain Inflammation in a Transgenic Mouse Model of Alzheimers Disease
Volume: 6 Issue: 5
Author(s): Sergey Kalinin, Jill C. Richardson and Douglas L. Feinstein
Affiliation:
Keywords: Amyloid, neprilysin, astrocyte, promoter, inflammation, NEP, IDE
Abstract: Agonists of the peroxisome proliferator activated receptor gamma (PPARγ) have been shown to reduce inflammatory responses in several animal models of neurological diseases and conditions and to reduce amyloid burden in transgenic mice expressing mutant forms of human amyloid precursor protein. However, the effects of activating the related receptor PPARdelta (PPARδ), which is expressed at higher levels in the brain than PPARγ, on inflammation and amyloid burden have not been explored. In this study we tested the effects of the selective PPARδ agonist GW742 in 5xFAD mice which harbor 3 mutations in amyloid precursor protein and 2 mutations in presenilin 1, develop plaques by 5-6 weeks of age, and show robust inflammation and neuronal damage. Oral delivery of GW742 significantly reduced amyloid plaque burden in the subiculum region of 3-month old male and female 5xFAD mice. GW742 also significantly reduced astrocyte activation, suggesting anti-inflammatory effects on glia cells. The changes in plaque burden were accompanied by increased expression of the amyloid degrading enzymes neprilysin and insulin degrading enzyme, while in transfected HEK293 cells, GW742 activated a neprilysin promoter driving luciferase expression. These results suggest that, as found for some PPARγ agonists, PPARδ agonists can also reduce amyloid burden likely to be mediated by effects on amyloid clearance.
Export Options
About this article
Cite this article as:
Kalinin Sergey, Richardson C. Jill and Feinstein L. Douglas, A PPARdelta Agonist Reduces Amyloid Burden and Brain Inflammation in a Transgenic Mouse Model of Alzheimers Disease, Current Alzheimer Research 2009; 6 (5) . https://dx.doi.org/10.2174/156720509789207949
DOI https://dx.doi.org/10.2174/156720509789207949 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Calpain and Its Involvement in the Pathophysiology of CNS Injuries and Diseases: Therapeutic Potential of Calpain Inhibitors for Prevention of Neurodegeneration
Current Drug Targets - CNS & Neurological Disorders VIP in Inflammatory Bowel Disease: State of the Art
Endocrine, Metabolic & Immune Disorders - Drug Targets Blood-Brain Barrier Transport of Cytokines: A Mechanism for Neuropathology
Current Pharmaceutical Design Functional Interactions Between B Lymphocytes and the Innate Immune System
Infectious Disorders - Drug Targets Diffusion Tensor Imaging to Determine Effects of Antidementive Treatment on Cerebral Structural Connectivity in Alzheimer’s Disease
Current Pharmaceutical Design The AKT Axis as a Therapeutic Target in Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Bis(thiosemicarbazone) Metal Complexes as Therapeutics for Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Use of Genetically Modified Bacteria to Modulate Adaptive Immunity
Current Gene Therapy Multifactorial Regulation of GPER Expression in Cancer Cells and Cardiomyocytes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Translocator Protein 18 kDa (TSPO) and Its Role in Mitochondrial Biology and Psychiatric Disorders
Mini-Reviews in Medicinal Chemistry Impact of IL-17 on Cells of the Monocyte Lineage in Health and Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Critical Questions for Preclinical Trials on Safety and Efficacy of Vascular Endothelial Growth Factor-Based Therapeutic Angiogenesis for Ischemic Stroke
CNS & Neurological Disorders - Drug Targets The Regulation of Neuroimmune-Endocrine Interactions: Mechanisms,Molecular Pathways Unraveled and the Pivotal Role of Cytokines – A Unsung Putative Bidirectional Interdependence between the Immune and Neuroendocrine Interfaces
Current Immunology Reviews (Discontinued) Tianeptine: A Novel Atypical Antidepressant that May Provide New Insights into the Biomolecular Basis of Depression
Recent Patents on CNS Drug Discovery (Discontinued) Withdrawn: Effects of Tofacitinib on Tfr/Tfh Balance and Expression of CXCL13 and TGF-β1 in Experimental Autoimmune Encephalomyelitis Rats
CNS & Neurological Disorders - Drug Targets Effects of Mefepronic Acid (2-Phenoxy-2-Methyl Propionic Acid) on Hepatic Metabolism and Reproductive Parameters in Postpartum Dairy Cows
Endocrine, Metabolic & Immune Disorders - Drug Targets Prostaglandin J2 Family and the Cardiovascular System
Current Vascular Pharmacology Selection of Microbial T-Cell Epitopes for Immune-Diagnosis, Immune- Therapy and Vaccine Design
Current Pharmacogenomics New Kid on the Block: Does Histamine Get Along with Inflammation in Amyotrophic Lateral Sclerosis?
CNS & Neurological Disorders - Drug Targets Possible Pathomechanisms Responsible for Injury to the Central Nervous System in the Settings of Chronic Cerebrospinal Venous Insufficiency
Reviews on Recent Clinical Trials